Safety and Efficacy of Inhaled Corticosteroids (ICS) in Children with Asthma

References

• National Asthma Education and Prevention Program. NAEPP Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma—Full Report 2007. National Institutes of Health, National Heart, Lung and Blood Institute, Bethesda, MD August, 2007
   Google Scholar
• Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). 2007, Available at http://www.ginasthma.org
   Google Scholar
• Jeffery P K, Godfrey R W, Adelroth E, et al. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. Am Rev Respir Dis 1992; 145: 890–899
   PubMed Web of Science ®Google Scholar
• Rao V U, Apter A J. Steroid phobia and adherence—problems, solutions, impact on benefit/risk profile. In: Skoner DP. Immunol Allergy Clin North America (Elsevier Saunders) 2005; 25: 581–596, (#3)
   PubMed Web of Science ®Google Scholar
• Szefler S J, Martin R J, King T S, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol Mar, 2002; 109(3)410–8
   PubMed Web of Science ®Google Scholar
• Szefler S J, Phillips B R, Martinez F D, Chinchilli V M, Lemanske R F, Strunk R C, Zeiger R S, Larsen G, Spahn J D, Bacharier L B, Bloomberg G R, Guilbert T W, Heldt G, Morgan W J, Moss M H, Sorkness C A, Taussig L M. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115(2)233–242
   PubMed Web of Science ®Google Scholar
• Chalmers G W, Macleod K J, Little S A, et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax Mar, 2002; 57(3)226–230
   PubMed Web of Science ®Google Scholar
• Peters-Golden M, Swern A, Bird S S, et al. Influence of body mass index on the response to asthma controller agents. Eur Respir J 2006; 27: 495–503
   PubMed Web of Science ®Google Scholar
• Tantisira K G, Lake S, Silverman E S, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet Jul 1, 2004; 13(13)1353–1359
   PubMed Web of Science ®Google Scholar
• Guilbert T W, Morgan W J, Zeiger R S, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006; 354(19)1985–1997
   PubMed Web of Science ®Google Scholar
• Wilson A M, McFarlane L C, Lipworth B J. Systemic bioavailability profiles of oral prednisolone and nebulized budesonide in adult asthmatics. Chest 1998; 114(4)1022–1027
   Google Scholar
• Skoner D P, Rachelefsky G S, Meltzer E O, Chervinsky P, Morris R M, Seltzer J M, Storms W W, Wood R A. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 2000; 105: E23
   PubMed Web of Science ®Google Scholar
• Lipworth B J. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 1999; 159(9)941–955
   PubMed Web of Science ®Google Scholar
• Szefler S, Rohatagi S, Williams J, Lloyd M, Kundu S, Banerji D. Ciclesonide, a Novel Inhaled Steroid, Does Not Affect Hypthalamic-Pituitary-Adrenal Axis function in Patients With Moderate-to-Severe Persistent Asthma. Chest 2005; 128: 1104–1114
   PubMed Web of Science ®Google Scholar
• Todd G, Dunlop K, McNaboe J, Ryan M F, Carson D, Shields M D. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet 1996; 348(9019)27–29
   Google Scholar
• Kewley G D. Possible association between beclomethasone diproprionate aerosol and cataracts. Aust Paediatr J Jun, 1980; 16(2)117–118
   Google Scholar
• Black R L, Oglesby R B, Von Sallmann L, Bunim J J. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA Sep 10, 1960; 174: 166–171
   PubMed Web of Science ®Google Scholar
• Simons F ER, Persaud M P, Gillespie C A, et al. Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids. Lancet 1993; 342: 776–778
   PubMed Web of Science ®Google Scholar
• Urban R C, Jr, Cotlier E. Corticosteroid-induced cataracts. Surv Ophthalmol Sep-Oct, 1986; 31(2)102–10
   PubMed Web of Science ®Google Scholar
• Bielory L. Ocular toxicity of systemic asthma and allergy treatments. Curr Allergy Asthma Rep Jul, 2006; 6(4)299–305
   Google Scholar
• Agertoft L, Larsen F E, Pedersen S. Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide. Eur Respir J 1998; 12(1)130–135
   Google Scholar
• Volovitz B, Amir J, Malik H, Kauschansky A, Varsano I. Growth and pituitary-adrenal function in children with severe asthma treated with inhaled budesonide. N Engl J Med Dec 2, 1993; 329(23)1703–8
   Google Scholar
• Cumming R G, Mitchell P, Leeder S R. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337(1)8–14
   PubMed Web of Science ®Google Scholar
• Garbe E, LeLorier J, Boivin J F, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997; 277(9)722–727
   PubMed Web of Science ®Google Scholar
• Mitchell P, Smith W, Chey T, Healey P R. Open-angle glaucoma and diabetes: the Blue Mountains eye study, Australia. Ophthalmology Apr, 1997; 104(4)712–8
   PubMedGoogle Scholar
• Wolff A H, Adelsberg B, Aloia J, Zitt M. Effect of inhaled corticosteroid on bone density in asthmatic patients: a pilot study. Ann Allergy Aug, 1991; 67: 117–21, (2 Pt 1)
   PubMedGoogle Scholar
• Israel E, Banerjee T R, Fitzmaurice G M, Kotlov T V, LaHive K, Le Boff M S. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med Sep 27, 2001; 345(13)941–7
   PubMed Web of Science ®Google Scholar
• Ducharme F M, Chabot G, Polychronakos C, Glorieux F, Mazer B. Safety profile of frequent short courses of oral glucocorticoids in acute pediatric asthma: impact on bone metabolism, bone density, and adrenal function. Pediatrics Feb, 2003; 111(2)376–83
   Google Scholar
• The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med Oct, 2000; 343(15)1054–63
   PubMed Web of Science ®Google Scholar
• Kelly H W, Van Natta M L, Covar R A, Tonascia J, Green R P, Strunk R C, CAMP Research Group. Effect of long-term corticosteroid use on bone mineral density in children: a prospective longitudinal assessment in the Childhood Asthma Management Program (CAMP) study. Pediatrics Jul, 2008; 122(1)e53–61
   PubMed Web of Science ®Google Scholar
• van Staa T P, Cooper C, Leufkens H G, Bishop N. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 2003; 18(5)913–918
   Google Scholar
• Schlienger R G, Jick S S, Meier C R. Inhaled corticosteroids and the risk of fractures in children and adolescents. Pediatrics 2004; 114(2)469–473
   Google Scholar
• Food and Drug Administration. Guidance for Industry: Orally Inhaled and Intranasal Corticosteroids: Evaluation of the Effects on Growth in Children—updated March 2007, Available from: http://www.fda.gov/cder/guidance/3787dft.pdf
   Google Scholar
• Covar R A, Leung D Y, McCormick D, et al. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol 2000; 106: 651–9
   PubMed Web of Science ®Google Scholar
• Martin R J, Szefler S J, Chinchilli V M, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med May 15, 2002; 165(10)1377–83
   PubMed Web of Science ®Google Scholar
• Verberne A A, Frost C, Duiverman E J, Grol M H, Kerrebjin K F. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group. Am J Respir Crit Care Med Jul, 1998; 158(1)213–19
   PubMedGoogle Scholar
• Heuck C, Wolthers O D, Kollerup G, Hansen M, Teisner B. Adverse effects of inhaled budesonide (800 micrograms) on growth and collagen turnover in children with asthma: A double-blind comparison of once-daily versus twice-daily administration. J Pediatr 1998; 133(5)608–612
   PubMedGoogle Scholar
• Heuck C, Heickendorff L, Wolthers O D. A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide. Arch Dis Child 2000; 83(4)334–339
   PubMed Web of Science ®Google Scholar
• Pedersen S. Clinical safety of inhaled corticosteroids for asthma in children: An update of long-term trials. Drug Saf 2006; 29(7)599–612
   PubMedGoogle Scholar
• Skoner D P, Welch M, Tinkelman D, Bagchi P, Raudenbush M A, Banerji D. Inhaled corticosteroid-induced growth retardation in asthmatic children in a “real world” setting. J Allergy Clin Immunology 1999; 103: S61
   Google Scholar
• Tinkelman D G, Reed C E, Nelson H S, Offord K P. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 1993; 92: 64–77
   PubMed Web of Science ®Google Scholar
• Doull I J, Freezer N J, Holgate S T. Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med 1995; 151(6)1715–1719
   Google Scholar
• Simons F ER, The Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. N Engl J Med 1997; 337: 1659–1665
   PubMed Web of Science ®Google Scholar
• Verberne A A, Frost C, Roorda R J, van der Laag H, Kerrebijn K F. One year treatment with salmeterol compared with beclomethasone in children with asthma. The dutch paediatric asthma study group. Am J Respir Crit Care Med 1997; 156: 688–695, (3 Pt 1)
   PubMed Web of Science ®Google Scholar
• Pedersen S, Warner J, Wahn U, et al. Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: An open-label, randomized comparison of extrafine and conventional aerosols in children. Pediatrics 2002; 109(6)e92
   Google Scholar
• Price J F, Russell G, Hindmarsh P C, et al. Growth during one year of treatment with fluticasone propionate or sodium cromoglycate in children with asthma. Pediatr Pulmonol 1997; 24: 178–186
   PubMed Web of Science ®Google Scholar
• Allen D B, Bronsky E A, LaForce C F, et al. Growth in asthmatic children treated with fluticasone propionate. Fluticasone propionate asthma study group. J Pediatr 1998; 132: 472–477, (3 Pt 1)
   PubMed Web of Science ®Google Scholar
• Schenkel E J, Skoner D P, Bronsky E A, Miller D, Pearlman D S, Rooklin A, Rosen J P, Ruff M E, Vanderwalker M L, Wanderer A, Damaraju C V, Nolop K B, Messarina-Wicki B. Absence of growth retardation in children with perennial allergic rhinitis following 1 year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000; 105: E22
   PubMed Web of Science ®Google Scholar
• Skoner D P, Gentile D, Angelini B, Kane R, Birdsall D, Banerji D. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol Jan, 2003; 90(1)56–62
   PubMed Web of Science ®Google Scholar
• Merkus P J, van Essen-Zandvliet E E, Duiverman E J, van Houwelingen H C, Kerrebijn K F, Quanjer P H. Long-term effect of inhaled corticosteroids on growth rate in adolescents with asthma. Pediatrics 1993; 91(6)1121–1126
   PubMed Web of Science ®Google Scholar
• Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88(5)373–381
   PubMed Web of Science ®Google Scholar
• Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000; 343(15)1064–1069
   PubMed Web of Science ®Google Scholar
• Jonasson G, Carlsen K H, Jonasson C, Mowinckel P. Low-dose inhaled budesonide once or twice daily for 27 months in children with mild asthma. Allergy 2000; 55(8)740–748
   PubMedGoogle Scholar
• Pauwels R A, Pedersen S, Busse W W, et al. Early intervention with budesonide in mild persistent asthma: A randomised, double-blind trial. Lancet 2003; 361(9363)1071–1076
   PubMed Web of Science ®Google Scholar
• Skoner D P, Dunn M, Lee T. Effects of mometasone furoate dry powder inhaler on growth velocity and HPA axis function in children with asthma. Am J Respir Crit Care Med 2003; 167(7)A272
   Google Scholar
• Becker A B, Kuznetsova O, Vermeulen J, et al. Pediatric Montelukast Linear Growth Study Group. Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study. Ann Allergy Asthma Immunol Jun, 2006; 96(6)800–7
   PubMed Web of Science ®Google Scholar
• Skoner D P, Maspero J, Banerji D, Ciclesonide Pediatric Growth Study Group. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics Jan, 2008; 121(1)e1–14
   Google Scholar
• Rohatagi S, Arya V, Zech K, Nave R, Hochhaus G, Jensen B K, et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol 2003; 43(4)365–78
   PubMed Web of Science ®Google Scholar
• Malozowski S. Comment on: Pediatrics 2008 Jan; 121(1):e1–14. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics Jul, 2008; 122(1)213, author reply 213
   Google Scholar
• Skoner D P. Balancing safety and effacacy in pediatric asthma management. Pediatrics 2002; 109(2)381–392
   Google Scholar
• Kayani S, Shannon D C. Adverse behavioral effects of treatment for acute exacerbation of asthma in children: a comparison of two doses of oral steroids. Chest Aug, 2002; 122(2)624–8
   PubMed Web of Science ®Google Scholar
• Chang A B, Clark R, Sloots T P, et al. A 5-versus 3-day course of oral corticosteroids for children with asthma exacerbations who are not hospitalised: a randomised controlled trial. Med J Aust Sep 15, 2008; 189(6)306–10
   Google Scholar